— Know what they know.
Not Investment Advice

DSGN NASDAQ

Design Therapeutics, Inc.
1W: -24.3% 1M: -17.6% 3M: +8.9% YTD: +21.0% 1Y: +200.0% 3Y: +75.3% 5Y: -52.1%
$10.97
-0.04 (-0.36%)
 
Weekly Expected Move ±16.2%
$10 $12 $14 $17 $19
NASDAQ · Healthcare · Biotechnology · Alpha Radar Sell · Power 30 · $685.2M mcap · 38M float · 1.54% daily turnover · Short 43% of daily vol

Cash Flow Trends

Operating Cash Flow
-$54M -26.1% ▼
Capital Expenditures
$193K +43.2% ▲
5Y CAGR: +20.5%
Free Cash Flow
-$55M -25.6% ▼
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
-$6M -518.7% ▼

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2021FY2022FY2023FY2024FY2025
— Operating Activities —
Net Income-$36M-$63M-$67M-$50M-$70M
Depreciation & Amort.$129K$406K$537K-$6M-$3M
Stock-Based Comp.$5M$11M$13M$13M$15M
Change in Working Capital$1M$2M$728K-$993K$3M
Other Non-Cash Items$19K-$1M-$6M$6K$406K
Operating Cash Flow-$29M-$51M-$59M-$43M-$54M
— Investing Activities —
Capital Expenditures-$2M-$918K-$256K-$340K-$193K
Acquisitions (Net)$52K$39K$0$0$0
Investment Purchases-$86M-$313M-$225M-$230M-$292M
Investment Sales$34M$93M$277M$274M$315M
Other Investing-$52K$0$0$0$0
Investing Cash Flow-$54M-$221M$53M$44M$23M
— Financing Activities —
Net Debt Issuance$0$0$0$0$0
Stock Repurchased$0$0$0$0$0
Dividends Paid$0$0$0$0$0
Other Financing$228K-$427K$0$0$0
Financing Cash Flow$379M$235K$724K$513K$26M
Net Change in Cash$296M-$272M-$5M$1M-$6M
Cash End of Period$299M$26M$21M$23M$17M
Free Cash Flow-$31M-$52M-$59M-$43M-$55M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms